CORCEPT THERAPEUTICS INC (CORT) Current Ratio
- Current ratio · latest quarter: Value 2.86×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.86× | Current assets / current liabilities. $439.68M ÷ $153.80M ≈ 2.86× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 439.68M USD | Assets, Current |
| Current obligations | 153.80M USD | Liabilities, Current |
| Cash and equivalents | 111.04M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 197.16M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 76.92M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 13.19M USD | Inventory, Net |
| Payables | 14.91M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $439.68M | $153.80M | $111.04M | $197.16M | $76.92M | $13.19M | $14.91M | (m) | 2.86× |
| 2026-03-31 | $426.03M | $149.19M | $108.74M | $229.45M | $39.07M | $12.89M | $33.31M | (m) | 2.86× |
| 2025-12-31 | $485.46M | $166.09M | $120.50M | $251.66M | $59.79M | $12.87M | $40.44M | (m) | 2.92× |
| 2025-09-30 | $541.13M | $172.26M | $125.14M | $296.55M | $69.63M | $12.35M | $34.45M | (m) | 3.14× |
| 2025-06-30 | $443.11M | $144.66M | $102.75M | $239.48M | $64.57M | $12.28M | $23.52M | (m) | 3.06× |
| 2025-03-31 | $438.50M | $143.07M | $89.82M | $232.94M | $61.82M | $14.37M | $27.95M | (m) | 3.07× |
| 2024-12-31 | $471.60M | $140.77M | $127.67M | $255.67M | $53.98M | $12.41M | $15.38M | (m) | 3.35× |
| 2024-09-30 | $466.98M | $126.22M | $137.29M | $243.05M | $59.72M | $8.05M | $18.58M | (m) | 3.70× |
| 2024-06-30 | $560.85M | $100.75M | $128.59M | $344.57M | $53.84M | $8.35M | $19.48M | (m) | 5.57× |
| 2024-03-31 | $503.37M | $97.20M | $149.75M | $261.01M | $61.52M | $7.19M | $12.56M | (m) | 5.18× |
| 2023-12-31 | $458.64M | $104.50M | $135.55M | $232.67M | $41.12M | $7.73M | $17.40M | (m) | 4.39× |
| 2023-09-30 | $431.53M | $121.87M | $111.80M | $243.43M | $34.63M | $7.51M | $16.71M | (m) | 3.54× |
| 2023-06-30 | $432.59M | $93.06M | $172.38M | $190.88M | $32.55M | $6.92M | $7.98M | (m) | 4.65× |
| 2023-03-31 | $533.89M | $78.86M | $299.94M | $165.12M | $32.56M | $6.41M | $11.22M | (m) | 6.77× |
| 2022-12-31 | $499.25M | $72.49M | $66.33M | $365.34M | $31.06M | $6.10M | $11.98M | (m) | 6.89× |
| 2022-09-30 | $452.40M | $53.07M | (m) | $346.02M | $29.41M | $6.05M | $8.18M | (m) | 8.52× |
| 2022-06-30 | $419.05M | $49.06M | $35.35M | $334.74M | $28.16M | $5.44M | $8.25M | (m) | 8.54× |
| 2022-03-31 | $388.22M | $57.24M | $61.86M | $283.67M | $27.18M | $5.08M | $9.27M | (m) | 6.78× |
| 2021-12-31 | $266.46M | $47.54M | $77.62M | $145.92M | $27.63M | $4.99M | $6.91M | (m) | 5.60× |
| 2021-09-30 | $401.90M | $44.76M | $94.69M | $266.64M | $26.51M | $4.99M | $6.56M | (m) | 8.98× |
| 2021-06-30 | $411.27M | $45.40M | $95.43M | $274.55M | $27.62M | $4.67M | $9.22M | (m) | 9.06× |
| 2021-03-31 | $409.62M | $40.60M | $52.38M | $320.58M | $22.20M | $4.95M | $6.97M | (m) | 10.09× |
| 2020-12-31 | $478.50M | $47.49M | $76.19M | $364.51M | $26.20M | $4.91M | $10.55M | (m) | 10.07× |
| 2020-09-30 | $463.49M | $43.05M | $30.56M | $398.23M | $21.96M | $4.82M | $6.51M | (m) | 10.77× |
| 2020-06-30 | $438.33M | $42.24M | $58.52M | $346.83M | $22.73M | $4.93M | $6.30M | (m) | 10.38× |
| 2020-03-31 | $344.78M | $34.08M | $84.48M | $222.84M | $26.68M | $5.08M | $4.98M | (m) | 10.12× |
| 2019-12-31 | $307.36M | $38.84M | $31.27M | $244.69M | $19.93M | $5.42M | $7.54M | (m) | 7.91× |
| 2019-09-30 | $267.31M | $32.40M | $44.95M | $186.70M | $22.41M | $5.46M | $5.94M | (m) | 8.25× |
| 2019-06-30 | $232.66M | $30.38M | $58.14M | $143.40M | $19.77M | $5.14M | $7.03M | (m) | 7.66× |
| 2019-03-31 | $216.86M | $34.22M | $49.65M | $137.25M | $19.22M | $5.00M | $9.33M | (m) | 6.34× |
| 2018-12-31 | $236.82M | $35.57M | $41.63M | $165.13M | $17.59M | $4.73M | $8.27M | (m) | 6.66× |
| 2018-09-30 | $224.19M | $40.21M | $33.89M | $161.30M | $19.36M | $5.36M | $13.92M | (m) | 5.58× |
| 2018-06-30 | $197.18M | $30.87M | $31.16M | $128.78M | $28.70M | $4.95M | $6.37M | (m) | 6.39× |
| 2018-03-31 | $150.82M | $27.75M | $33.12M | $92.24M | $17.26M | $4.88M | $7.85M | (m) | 5.44× |
| 2017-12-31 | $124.19M | $29.57M | $31.06M | $57.68M | $15.30M | $4.58M | $8.58M | (m) | 4.20× |
| 2017-09-30 | $93.94M | $24.37M | $31.06M | $44.10M | $11.87M | $3.83M | $6.23M | $0.00 | 3.85× |
| 2017-06-30 | $81.28M | $20.39M | $33.62M | $32.54M | $9.50M | $3.09M | $2.08M | $4.57M | 3.99× |
| 2017-03-31 | $66.67M | $25.76M | $37.98M | $14.80M | $9.21M | $2.89M | $4.25M | $10.11M | 2.59× |
| 2016-12-31 | $65.69M | $27.37M | $51.54M | $0.00 | $9.86M | $2.33M | $2.29M | $14.66M | 2.40× |
| 2016-09-30 | $59.78M | $31.68M | $47.87M | (m) | $8.24M | $2.33M | $4.31M | $18.73M | 1.89× |
| 2016-06-30 | $54.78M | $27.43M | $41.79M | (m) | $9.30M | $2.13M | $2.08M | $18.56M | 2.00× |
| 2016-03-31 | $50.51M | $24.02M | $40.74M | (m) | $6.75M | $1.91M | $2.08M | $16.32M | 2.10× |
| 2015-12-31 | $48.98M | $20.88M | $40.44M | (m) | $6.22M | $1.68M | $1.32M | $14.96M | 2.35× |
| 2015-09-30 | $45.18M | $18.77M | $36.45M | (m) | $5.95M | $1.60M | $1.74M | $13.51M | 2.41× |
| 2015-06-30 | $44.69M | $17.43M | $37.05M | (m) | $4.95M | $1.45M | $2.36M | $12.03M | 2.56× |
| 2015-03-31 | $44.19M | $15.53M | $37.95M | (m) | $4.30M | $1.31M | $1.04M | $10.66M | 2.85× |
| 2014-12-31 | $30.23M | $13.55M | $24.25M | (m) | $3.33M | $1.21M | $1.89M | $9.42M | 2.23× |
| 2014-09-30 | $32.38M | $12.49M | $26.78M | (m) | $2.75M | $1.08M | $1.96M | $8.66M | 2.59× |
| 2014-06-30 | $39.44M | $13.30M | $33.97M | (m) | $2.23M | $1.07M | $2.60M | $7.40M | 2.96× |
| 2014-03-31 | $48.12M | $15.24M | $43.62M | (m) | $1.92M | $1.13M | $3.67M | $6.90M | 3.16× |
| 2013-12-31 | $58.31M | $12.74M | $54.88M | (m) | $1.43M | $1.10M | $2.38M | $5.74M | 4.58× |
| 2013-09-30 | $66.22M | $10.14M | $63.17M | (m) | $1.02M | $1.02M | $2.34M | $4.50M | 6.53× |
| 2013-06-30 | $74.57M | $9.08M | $72.22M | (m) | $855.00K | $694.00K | $3.03M | $3.65M | 8.21× |
| 2013-03-31 | $84.20M | $8.24M | $81.46M | (m) | $1.14M | $1.03M | $2.26M | $3.90M | 10.21× |
| 2012-12-31 | $95.06M | $8.36M | $93.03M | (m) | $557.00K | $853.00K | $3.80M | $2.65M | 11.37× |
| 2012-09-30 | $104.62M | $5.55M | $101.63M | (m) | $354.00K | $1.84M | $1.57M | $2.25M | 18.86× |
| 2012-06-30 | $38.30M | $5.82M | $34.90M | (m) | $355.00K | $2.44M | $4.24M | (m) | 6.59× |
| 2012-03-31 | $42.78M | $3.57M | $42.63M | (m) | (m) | $56.00K | $2.08M | (m) | 11.98× |
| 2011-12-31 | $39.77M | $5.03M | $39.63M | (m) | (m) | (m) | $3.61M | (m) | 7.91× |
| 2011-09-30 | $46.34M | $2.71M | $45.91M | (m) | (m) | (m) | $1.07M | (m) | 17.08× |
| 2011-06-30 | $52.69M | $3.86M | $52.23M | (m) | (m) | (m) | $2.29M | (m) | 13.66× |
| 2010-12-31 | $25.00M | $3.86M | $24.58M | (m) | (m) | (m) | $817.00K | (m) | 6.48× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |